Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23215741 | 0.93 | GPR119 (0.54) | GPR119KCNH2CYP4F2CYP4A11 | |
| SCHEMBL29843824 | 0.93 | GPR119 (0.54) | GPR119KCNH2CYP4F2CYP4A11 | |
| SCHEMBL23216080 | 0.92 | GPR119 (0.64) | GPR119KCNH2 | |
| SCHEMBL23215579 | 0.91 | GPR119 (0.52) | GPR119KCNH2KDM1A | |
| SCHEMBL29843754 | 0.91 | GPR119 (0.52) | GPR119KCNH2KDM1A | |
| SCHEMBL29843778 | 0.91 | GPR119 (0.64) | GPR119KCNH2 | |
| SCHEMBL23215867 | 0.91 | GPR119 (0.64) | GPR119KCNH2 | |
| SCHEMBL23215907 | 0.91 | GPR119 (0.65) | GPR119KCNH2 | |
| SCHEMBL23226218 | 0.91 | GPR119 (0.55) | GPR119KCNH2 | |
| SCHEMBL29843768 | 0.91 | GPR119 (0.65) | GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061736-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230061736-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11512065-B2 | GPR119 agonists | KALLYOPE, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-4041722-A1 | GPR119 AGONISTS | Kallyope, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153719-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2022-05-19 | — | — | US | disclosed |
| WO-2021071837-A1 | GPR119 AGONISTS | KALLYOPE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071837-A1 | GPR119 AGONISTS | KALLYOPE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512065-B2 | GPR119 agonists | GPR119, GLP1R, GCGR | GPR119 1/4885KCNH2 4507/4885KDM1A 1524/4885 |
| US-20230061736-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | GPR119 1/4885KCNH2 4507/4885KDM1A 1524/4885 |
| US-20220153719-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | GPR119 1/4885KCNH2 4507/4885KDM1A 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.